Multiple clinical effects of recombinant human growth hormone therapy

Bin ZHOU, Yu YANG

Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (7) : 797-804.

PDF(607 KB)
HTML
PDF(607 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2026, Vol. 28 ›› Issue (7) : 797-804. DOI: 10.7499/j.issn.1008-8830.2601142
SERIES REVIEW—DIAGNOSIS AND TREATMENT OF GROWTH DISORDERS

Multiple clinical effects of recombinant human growth hormone therapy

Author information +
History +

Abstract

Recombinant human growth hormone (rhGH) is the main therapeutic approach for height improvement. In recent years, with deepening research and clinical practice, accumulating evidence indicates that rhGH exerts additional clinical benefits on body composition, lipid metabolism, the skeletal system, and cognitive function. This article systematically reviews the multiple clinical effects of rhGH to provide a reference for optimizing treatment strategies and improving long-term health outcomes in patients.

Key words

Recombinant human growth hormone / Lipid metabolism / Body composition / Cognitive function / Skeletal system

Cite this article

Download Citations
Bin ZHOU , Yu YANG. Multiple clinical effects of recombinant human growth hormone therapy[J]. Chinese Journal of Contemporary Pediatrics. 2026, 28(7): 797-804 https://doi.org/10.7499/j.issn.1008-8830.2601142

References

[1]
潘慧, 杜红伟. 重组人生长激素临床应用的安全性思考[J]. 中国当代儿科杂志, 2024, 26(5): 444-449. PMCID: PMC11135066. DOI: 10.7499/j.issn.1008-8830.2310001 .
[2]
Ferruzzi A, Vrech M, Pietrobelli A, et al. The influence of growth hormone on pediatric body composition: a systematic review[J]. Front Endocrinol (Lausanne), 2023, 14: 1093691. PMCID: PMC9947344. DOI: 10.3389/fendo.2023.1093691 .
[3]
Yuan Y, Zhou B, Liu S, et al. Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy[J]. Endocrine, 2021, 71(1): 35-46. DOI: 10.1007/s12020-020-02435-w .
[4]
Frixou M, Vlek D, Lucas-Herald AK, et al. The use of growth hormone therapy in adults with Prader-Willi syndrome: a systematic review[J]. Clin Endocrinol (Oxf), 2021, 94(4): 645-655. DOI: 10.1111/cen.14372 .
[5]
Shen YY, Ma JN, Ren ZY, et al. Effects of 18 months of growth hormone replacement therapy on bone mineral density in patients with adult growth hormone deficiency: a retrospective study[J]. Int J Endocrinol, 2023, 2023: 4988473. PMCID: PMC10081901. DOI: 10.1155/2023/4988473 .
[6]
Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis[J]. J Clin Endocrinol Metab, 2014, 99(3): 852-860. DOI: 10.1210/jc.2013-3921 .
[7]
Chaplin JE, Kriström B, Jonsson B, et al. Growth hormone treatment improves cognitive function in short children with growth hormone deficiency[J]. Horm Res Paediatr, 2015, 83(6): 390-399. DOI: 10.1159/000375529 .
[8]
Falleti MG, Maruff P, Burman P, et al. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature[J]. Psychoneuroendocrinology, 2006, 31(6): 681-691. DOI: 10.1016/j.psyneuen.2006.01.005 .
[9]
Aghili ZS, Khoshnevisan G, Mostoli R, et al. Growth hormone signaling and clinical implications: from molecular to therapeutic perspectives[J]. Mol Biol Rep, 2025, 52(1): 202. DOI: 10.1007/s11033-025-10304-w .
[10]
Fernández-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, et al. Growth hormone and aging: a clinical review[J]. Front Aging, 2025, 6: 1549453. PMCID: PMC12009952. DOI: 10.3389/fragi.2025.1549453 .
[11]
Sharma VM, Vestergaard ET, Jessen N, et al. Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes[J]. Am J Physiol Endocrinol Metab, 2019, 316(1): E34-E42. PMCID: PMC6417689. DOI: 10.1152/ajpendo.00129.2018 .
[12]
Kopchick JJ, Berryman DE, Puri V, et al. The effects of growth hormone on adipose tissue: old observations, new mechanisms[J]. Nat Rev Endocrinol, 2020, 16(3): 135-146. PMCID: PMC7180987. DOI: 10.1038/s41574-019-0280-9 .
[13]
Li T, Bai H, Fang H, et al. Growth hormone inhibits adipogenic differentiation and induces browning in bovine subcutaneous adipocytes[J]. Growth Horm IGF Res, 2022, 66: 101498. DOI: 10.1016/j.ghir.2022.101498 .
[14]
Wydra A, Czajka-Oraniec I, Wydra J, et al. The influence of growth hormone deficiency on bone health and metabolisms[J]. Reumatologia, 2023, 61(4): 239-247. PMCID: PMC10515129. DOI: 10.5114/reum/170244 .
[15]
Yuen KCJ. Growth hormone and bone: preclinical and clinical perspectives[J]. Endocr Pract, 2025, 31(9): 1197-1206. DOI: 10.1016/j.eprac.2025.07.005 .
[16]
Bolamperti S, Villa I, di Filippo L. Growth hormone and bone: a basic perspective[J]. Pituitary, 2024, 27(6): 745-751. DOI: 10.1007/s11102-024-01464-2 .
[17]
Soler Palacios B, Nieto C, Fajardo P, et al. Growth hormone reprograms macrophages toward an anti-inflammatory and reparative profile in an MAFB-dependent manner[J]. J Immunol, 2020, 205(3): 776-788. DOI: 10.4049/jimmunol.1901330 .
[18]
Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system[J]. Growth Horm IGF Res, 2009, 19(3): 187-197. DOI: 10.1016/j.ghir.2008.12.001 .
[19]
Huang Z, Xiao L, Xiao Y, et al. The modulatory role of growth hormone in inflammation and macrophage activation[J]. Endocrinology, 2022, 163(8): bqac088. DOI: 10.1210/endocr/bqac088 .
[20]
Menezes F, Wasinski F, de Souza GO, et al. The pattern of GH action in the mouse brain[J]. Endocrinology, 2024, 165(7): bqae057. PMCID: PMC11137758. DOI: 10.1210/endocr/bqae057 .
[21]
Aguiar-Oliveira MH, Boguszewski MCS, Rovaris DL, et al. Growth hormone and IGF-1 actions in the brain and neuropsychiatric diseases[J]. Physiology (Bethesda), 2026, 41(1): 3-15. PMCID: PMC12290765. DOI: 10.1152/physiol.00009.2025 .
[22]
Donato J, Kopchick JJ. New findings on brain actions of growth hormone and potential clinical implications[J]. Rev Endocr Metab Disord, 2024, 25(3): 541-553. PMCID: PMC11156798. DOI: 10.1007/s11154-023-09861-x .
[23]
Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association[J]. Circulation, 2016, 134(23): e579-e646. DOI: 10.1161/CIR.0000000000000455 .
[24]
Marra AM, D'Assante R, De Luca M, et al. Growth hormone replacement therapy in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial[J]. JACC Heart Fail, 2025, 13(4): 602-614. DOI: 10.1016/j.jchf.2024.11.017 .
[25]
Ferrigno R, Savanelli MC, Cioffi D, et al. Auxological and metabolic effects of long-term treatment with recombinant growth hormone in children born small for gestational age: a retrospective study[J]. Endocrine, 2024, 84(1): 213-222. DOI: 10.1007/s12020-023-03665-4 .
[26]
Kim S, Kim SJ, Cho KW, et al. Metabolic changes after growth hormone treatment in children with growth hormone deficiency and small for gestational age: LG observational study[J]. Front Endocrinol (Lausanne), 2025, 16: 1661018. PMCID: PMC12672343. DOI: 10.3389/fendo.2025.1661018 .
[27]
Zhou Z, Xiao S, Guo X, et al. Metabolic profiles of Turner syndrome: a real-world cohort study[J]. Medicina Clínica, 2025, 165(4): 107061. DOI: 10.1016/j.medcli.2025.107061 .
[28]
Rosenberg AGW, Passone CGB, Pellikaan K, et al. Growth hormone treatment for adults with Prader-Willi syndrome: a meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106(10): 3068-3091. PMCID: PMC8475230. DOI: 10.1210/clinem/dgab406 .
[29]
Kawai M, Murakami N, Horikawa R, et al. Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort phase 3 study[J]. Endocr J, 2025, 72(8): 925-935. PMCID: PMC12340246. DOI: 10.1507/endocrj.EJ24-0659 .
[30]
Kühl AM, Tortorella CCS, Almeida CCB, et al. Growth hormone effect on body composition of children born small for gestational age: a systematic review[J]. J Pediatr (Rio J), 2023, 99(3): 219-227. PMCID: PMC10202731. DOI: 10.1016/j.jped.2022.11.010 .
[31]
Ari M, Bakalov VK, Hill S, et al. The effects of growth hormone treatment on bone mineral density and body composition in girls with Turner syndrome[J]. J Clin Endocrinol Metab, 2006, 91(11): 4302-4305. DOI: 10.1210/jc.2006-1351 .
[32]
Kucharska A, Witkowska-Sędek E, Erazmus M, et al. The effects of growth hormone treatment beyond growth promotion in patients with genetic syndromes: a systematic review of the literature[J]. Int J Mol Sci, 2024, 25(18): 10169. PMCID: PMC11432634. DOI: 10.3390/ijms251810169 .
[33]
Stagi S, Ferrari V, Ferrari M, et al. Inside the Noonan "universe": literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns[J]. Front Endocrinol (Lausanne), 2022, 13: 951331. PMCID: PMC9434367. DOI: 10.3389/fendo.2022.951331 .
[34]
Cho MH, An SJ, Shim YS, et al. Impact of growth hormone therapy on bone and body composition in prepubertal children with idiopathic short stature[J]. J Pediatr Endocrinol Metab, 2025, 38(6): 624-630. DOI: 10.1515/jpem-2025-0085 .
[35]
Madeo SF, Zagaroli L, Vandelli S, et al. Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlation[J]. Front Endocrinol (Lausanne), 2024, 15: 1382583. PMCID: PMC11082343. DOI: 10.3389/fendo.2024.1382583 .
[36]
Lem AJ, van der Kaay DC, Hokken-Koelega AC. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment[J]. J Clin Endocrinol Metab, 2013, 98(1): 77-86. DOI: 10.1210/jc.2012-2492 .
[37]
Xu Q, Yang Y, Ke J, et al. Effect of growth hormone on bone density and body composition in Chinese patients with transitional growth hormone deficiency[J]. Medicine (Baltimore), 2025, 104(35): e44178. PMCID: PMC12401361. DOI: 10.1097/MD.0000000000044178 .
[38]
Szybiak W, Kujawa B, Miedziaszczyk M, et al. Effect of growth hormone and estrogen replacement therapy on bone mineral density in women with Turner syndrome: a meta-analysis and systematic review[J]. Pharmaceuticals (Basel), 2023, 16(9): 1320. PMCID: PMC10536543. DOI: 10.3390/ph16091320 .
[39]
Weinberg A, Dror N, Motin K, et al. The effect of growth hormone treatment on physical performance indices in children with idiopathic short stature[J]. Pediatr Exerc Sci, 2021, 33(2): 70-73. DOI: 10.1123/pes.2020-0061 .
[40]
Donze SH, Damen L, Mahabier EF, et al. Cognitive functioning in children with Prader-Willi syndrome during 8 years of growth hormone treatment[J]. Eur J Endocrinol, 2020, 182(4): 405-411. DOI: 10.1530/EJE-19-0479 .
[41]
Ayet-Roger A, Joga-Elvira L, Caixàs A, et al. Cognitive and adaptive effects of early growth hormone treatment in Prader-Willi syndrome patients: a cohort study[J]. J Clin Med, 2022, 11(6): 1592. PMCID: PMC8955812. DOI: 10.3390/jcm11061592 .
[42]
van Pareren YK, Duivenvoorden HJ, Slijper FS, et al. Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age[J]. J Clin Endocrinol Metab, 2004, 89(11): 5295-5302. DOI: 10.1210/jc.2003-031187 .
[43]
Ross JL, Feuillan P, Kushner H, et al. Absence of growth hormone effects on cognitive function in girls with Turner syndrome[J]. J Clin Endocrinol Metab, 1997, 82(6): 1814-1817. DOI: 10.1210/jcem.82.6.4003 .
[44]
Rovet JF, Van Vliet G. Growth hormone supplementation and psychosocial functioning to adult height in Turner syndrome: a questionnaire study of participants in the Canadian randomized trial[J]. Front Endocrinol (Lausanne), 2019, 10: 125. PMCID: PMC6425861. DOI: 10.3389/fendo.2019.00125 .
[45]
Shemesh-Iron M, Lazar L, Lebenthal Y, et al. Growth hormone therapy and short stature-related distress: a randomized placebo-controlled trial[J]. Clin Endocrinol (Oxf), 2019, 90(5): 690-701. DOI: 10.1111/cen.13944 .
[46]
Phillip M, Abuzzahab MJ, Pietropoli A, et al. Comparative outcomes of GH treatment in pediatric idiopathic short stature and GH deficiency[J]. J Endocr Soc, 2025, 9(10): bvaf133. PMCID: PMC12448476. DOI: 10.1210/jendso/bvaf133 .
[47]
Elbornsson M, Horvath A, Götherström G, et al. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency[J]. Eur J Endocrinol, 2017, 176(2): 99-109. DOI: 10.1530/EJE-16-0875 .
[48]
Rodrígez JMR, Toda LI, López ID, et al. Adult height and health-related quality of life in patients born small for gestational age treated with recombinant growth hormone[J]. Sci Rep, 2023, 13(1): 3135. PMCID: PMC9950462. DOI: 10.1038/s41598-023-30281-z .
[49]
Bakker NE, Siemensma EP, van Rijn M, et al. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study[J]. Horm Res Paediatr, 2015, 84(4): 231-239. DOI: 10.1159/000437141 .
[50]
Krantz E, Landin-Wilhelmsen K, Trimpou P, et al. Health-related quality of life in Turner syndrome and the influence of growth hormone therapy: a 20-year follow-up[J]. J Clin Endocrinol Metab, 2019, 104(11): 5073-5083. PMCID: PMC6760289. DOI: 10.1210/jc.2019-00340 .
[51]
Alkan F, Ersoy B, Kızılay DO, et al. Cardiac functions in children with growth hormone deficiency: effects of one year of GH replacement therapy[J]. Growth Horm IGF Res, 2021, 60-61: 101432. DOI: 10.1016/j.ghir.2021.101432 .
[52]
Sävendahl L, Polak M, Backeljauw P, et al. Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER[J]. J Clin Endocrinol Metab, 2021, 106(6): 1728-1741. PMCID: PMC8118578. DOI: 10.1210/clinem/dgab080 .

Footnotes

所有作者均声明无利益冲突。

PDF(607 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/